TABLE 3.
Susceptibility of Candida guilliermondii to fluconazole and voriconazole by clinical service
| Clinical service (total no. of isolates)a | Antifungal agent | No. of isolates tested (%)b | % of isolates from servicec | % of isolates
|
||
|---|---|---|---|---|---|---|
| S | SDD | R | ||||
| Hematology-oncology (4,635) | Fluconazole | 47 (4.6) | 1.0 | 78.7 | 6.4 | 14.9 |
| Voriconazole | 32 (5.1) | 96.9 | 3.1 | |||
| Medical (17,408) | Fluconazole | 159 (15.4) | 0.9 | 79.9 | 13.2 | 6.9 |
| Voriconazole | 124 (19.6) | 93.5 | 3.2 | 3.2 | ||
| Surgical (5,126) | Fluconazole | 51 (5.0) | 0.9 | 68.6 | 23.5 | 7.8 |
| Voriconazole | 47 (7.4) | 91.5 | 4.3 | 4.3 | ||
| Intensive care unit (10,052) | Fluconazole | 67 (6.5) | 0.7 | 79.1 | 11.9 | 9.0 |
| Voriconazole | 55 (8.7) | 90.9 | 1.8 | 7.3 | ||
| Dermatology (1,457) | Fluconazole | 158 (15.3) | 10.8 | 57.6 | 24.1 | 18.4 |
| Voriconazole | 121 (19.1) | 90.9 | 6.6 | 2.5 | ||
| Urology (649) | Fluconazole | 14 (1.4) | 2.2 | 78.6 | 7.1 | 14.3 |
| Voriconazole | 6 (0.9) | 83.3 | 16.7 | |||
| Outpatient (6,414) | Fluconazole | 47 (4.6) | 0.7 | 74.5 | 10.6 | 14.9 |
| Voriconazole | 25 (3.9) | 84.0 | 8.0 | 8.0 | ||
| Other, NOS (30,020) | Fluconazole | 486 (47.2) | 1.6 | 79.2 | 11.5 | 9.3 |
| Voriconazole | 223 (35.2) | 90.1 | 3.2 | 6.7 | ||
a
Total number of Candida isolates from each service.
b
Percentage of all C. guilliermondii isolates tested.
c
C. guilliermondii as a percentage of all isolates from that clinical service.